Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Cerilliant
Moodys
Julphar
Deloitte
Baxter
Teva
AstraZeneca
Covington

Generated: August 16, 2018

DrugPatentWatch Database Preview

INVOKANA Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Invokana patents expire, and when can generic versions of Invokana launch?

Invokana is a drug marketed by Janssen Pharms and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and ten patent family members in forty-three countries.

The generic ingredient in INVOKANA is canagliflozin. There are twenty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the canagliflozin profile page.

Drug patent expirations by year for INVOKANA
Generic Entry Opportunity Date for INVOKANA
Generic Entry Date for INVOKANA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Medical Subject Heading (MeSH) Categories for INVOKANA
Synonyms for INVOKANA
(1S)-1,5-Anhydro-1-(3-((5-(4-fluorophenyl)-2-thienyl)methyl)-4-methylphenyl)-D-glucitol
(1S)-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methyl-phenyl)-D-glucitol
(1S)-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methylphenyl)-D-glucitol
(1s)-1,5-anhydro-1-c-(3-((5-(4-fluorophenyl)-2-thienyl)methyl)-4-methylphenyl)-d-glucitol
(1S)-1,5-Anhydro-1-c-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-D-glucitol
(1S)-1,5-Anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol
(2S,3R,4R,5S,6R)-2-(3-((5-(4-FLUOROPHENYL)THIOPHEN-2-YL)METHYL)-4-METHYLPHENYL)-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL
(2S,3R,4R,5S,6R)-2-(3-((5-(4-FLUOROPHENYL)THIOPHEN-2-YL)METHYL)-4-METHYLPHENYL)-TETRAHYDRO-6-(HYDROXYMETHYL)-2H-PYRAN-3,4,5-TRIOL
(2S,3R,4R,5S,6R)-2-(3-{[5-(4-fluorophenyl)thiophen-2-yl]methyl}-4-methylphenyl)-6-(hydroxymethyl)oxane-3,4,5-triol
1-(Glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene
6S49DGR869
842133-18-0
928672-86-0
ABP000358
AC-26303
ACN-034470
AJ-108287
AKOS025401827
API0013707
BC638828
BCP9000477
BCPP000303
BDBM50386885
C24H25FO5S
Canagliflozin
Canagliflozin [INN]
Canagliflozin anhydrous
canagliflozin hemihydrate
Canagliflozin hydrate
Canagliflozin/
Canagliflozin/metformin
CC0249
CCG-229581
CHEBI:73274
CHEMBL2048484
CS-0522
D-Glucitol, 1,5-anhydro-1-C-(3-((5-(4-fluorophenyl)-2-thienyl)methyl)-4- methylphenyl)-, (1S)-
D-glucitol, 1,5-anhydro-1-c-(3-((5-(4-fluorophenyl)-2-thienyl)methyl)-4- methylphenyl)-, (1s)-
D-Glucitol, 1,5-anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-, (1S)-
D08DFX
D0S8XP
DB08907
FT-0664217
GLU008
GTPL4582
HSDB 8284
HY-10451
J-500391
JNJ 24831754
JNJ 24831754AAA
JNJ 24831754ZAE
JNJ-28431754
KB-271653
KB-75871
KS-1443
MFCD18251436
MLS006011126
MolPort-021-804-941
PB22925
Q-4516
RL05180
s2760
SCHEMBL157162
SMR004702906
TA 7284
TA-7284
Tube102
UNII-6S49DGR869
XTNGUQKDFGDXSJ-ZXGKGEBGSA-N
Y0287
ZINC43207238

US Patents and Regulatory Information for INVOKANA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Pharms INVOKANA canagliflozin TABLET;ORAL 204042-001 Mar 29, 2013 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Janssen Pharms INVOKANA canagliflozin TABLET;ORAL 204042-001 Mar 29, 2013 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Janssen Pharms INVOKANA canagliflozin TABLET;ORAL 204042-001 Mar 29, 2013 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Paragraph IV (Patent) Challenges for INVOKANA
Drugname Dosage Strength RLD Date
➤ Subscribe Tablets 100 mg and 300 mg ➤ Subscribe ➤ Sign Up

Non-Orange Book US Patents for INVOKANA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,511,020 Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides ➤ Sign Up
8,202,984 Glucopyranoside compound ➤ Sign Up
7,084,124 Substituted indazole-O-glucosides ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for INVOKANA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2014008 Lithuania ➤ Sign Up PRODUCT NAME: CANAGLIFOZINUM; REGISTRATION NO/DATE: EU/1/13/884/001 - EU/1/13/884/004, 2013 11 15 EU/1/13/884/005 - EU/1/13/884/008 20131115
426 Luxembourg ➤ Sign Up PRODUCT NAME: CANAGLIFLOZINE
00670 Netherlands ➤ Sign Up PRODUCT NAME: CANAGLIFLOZINE; REGISTRATION NO/DATE: EU/1/13/884/001-008 20131118
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
QuintilesIMS
Fuji
Deloitte
Argus Health
Express Scripts
Daiichi Sankyo
Boehringer Ingelheim
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.